The California-Arizona and Oregon/Hawaii Nodes of the National Drug Abuse Treatment Clinical Trials Network (CTN) integrated their Regional Research and Training Centers (RRTCs) and, in partnership with their community treatment programs (CTPs), combined to propose the Western States Node. In addition to its charter treatment partners, the node expands to include Colorado's network of addiction treatment services - Signal Behavioral Health Network;Signal has prior CTN experience in the Rocky Mountain Node. This competing renewal application has one goal: Promote evidence-based drug abuse prevention and treatment services through our continued participation in the National Drug Abuse Treatment Clinical Trials Network: Design and implement clinical trials of behavioral, pharmacological and combined interventions for drug use disorders through rapid recruitment of diverse study participants in partnership with NIDA and the CTN. Generate peer-reviewed publications in collaboration with treatment providers and other nodes, and Use the CTN as a platform for training, dissemination, and research applications. During the current funding period the California-Arizona and Oregon/Hawaii Nodes, together demonstrated high-quality participation in 12 CTN multi-site clinical trials, involving 13 CTPs and randomizing 900 protocol participants. Node investigators co-led CTN trials of HIV Risk Reduction (CTN0017) and HIV Rapid Testing (CTN0032). Node investigators also sought and received awards for 11 studies that used the CTN as a platform for research. The Western States Node research agenda proposes using the CTN to collaborate with health plans and/or addiction treatment centers to test prevention and treatment interventions directed at reducing the misuse and abuse of prescription opiates. Closing the gap between research and treatment is one of the most critical unresolved issues in drug abuse, and the CTN has a significant role. Based on the Western States Node's experience, access to unique and hard-to-reach populations, and a knowledgeable team of investigators and CTPs, this research node has the potential to accelerate the advancement of clinical trials and translational research in the coming years.

Public Health Relevance

This renewal application to continue conducting translational research in the NIDA Clinical Trials Network has broad public health implications. It focuses on three highly-significant health problems: Drug abuse, HIV/ AIDS, and heath disparities. The project will! conduct clinical trials of treatments for drug use disorders. The project's research agenda will address reducing the abuse of prescription opiates. The project will enable us to identify the effectiveness of these treatments as well as their applicability to a range of hard-to-reach populations. This research can accelerate the advancement of drug abuse treatments in the coming years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA015815-10S2
Application #
8459183
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2002-09-30
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
10
Fiscal Year
2012
Total Cost
$1,078,001
Indirect Cost
$5,184
Name
University of California San Francisco
Department
Psychiatry
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2017) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav :
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Korthuis, Philip T; Lum, Paula J; Vergara-Rodriguez, Pamela et al. (2017) Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction 112:1036-1044
Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209
Lee, J D; Tofighi, B; McDonald, R et al. (2017) Acceptability and effectiveness of a web-based psychosocial intervention among criminal justice involved adults. Health Justice 5:3
Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70
Campbell, Aimee N C; Montgomery, L; Sanchez, Katherine et al. (2017) Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders. J Ethn Subst Abuse 16:460-478
Hser, Yih-Ing; Evans, Elizabeth; Huang, David et al. (2016) Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111:695-705

Showing the most recent 10 out of 154 publications